Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Age and cytogenetics as predictors of event free survival in patients withacute non-lymphocytic leukemia receiving high dose cytosine arabinoside and daunorubicin as consolidation chemotherapy
Autore:
Stein, RS; Wolff, SN; Greer, JP; Flexner, JM; Goodman, S; Jagasia, M; Brandt, SJ; Morgan, DS; Arrowsmith, E; McCurley, TL;
Indirizzi:
Vanderbilt Univ, Sch Med, Dept Med, Div Hematol & Oncol, Nashville, TN USAVanderbilt Univ Nashville TN USA Div Hematol & Oncol, Nashville, TN USA Vanderbilt Univ, Sch Med, Dept Pathol, Div Hematopathol, Nashville, TN USAVanderbilt Univ Nashville TN USA ol, Div Hematopathol, Nashville, TN USA VA Med Ctr, Nashville, TN USA VA Med Ctr Nashville TN USAVA Med Ctr, Nashville, TN USA
Titolo Testata:
LEUKEMIA & LYMPHOMA
fascicolo: 5, volume: 42, anno: 2001,
pagine: 913 - 922
SICI:
1042-8194(200109/10)42:5<913:AACAPO>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYELOID-LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; BONE-MARROW TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIA; 1ST REMISSION; THERAPY; CYTARABINE; ETOPOSIDE; RELAPSE; TRIAL;
Keywords:
acute non-lymphocytic leukemia; prognostic features; age; cytogenetics;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Stein, RS Vanderbilt Univ, Med Ctr, 2617 TVC,1301 22nd Ave S, Nashville, TN 37232 USA Vanderbilt Univ 2617 TVC,1301 22nd Ave S Nashville TN USA 37232
Citazione:
R.S. Stein et al., "Age and cytogenetics as predictors of event free survival in patients withacute non-lymphocytic leukemia receiving high dose cytosine arabinoside and daunorubicin as consolidation chemotherapy", LEUK LYMPH, 42(5), 2001, pp. 913-922

Abstract

Between 1991 and 1999, 67 patients with acute non-lymphocytic leukemia (ANLL) in complete remission received high dose cytarabine (HiDAC) 3 gm/m(2) q12h x 12 doses followed by daunorubicin 45 mg/m(2)/day x 3 days as consolidation therapy. Five year actuarial event free survival (EFS) was 34% +/- 6%. Age was significantly associated with EFS. EFS was 60% +/- 15% in patients age 20 to 29, 48% +/- 16% in patients age 30 to 39, 23% +/- 10% in patients age 40 to 49, 31% +/- 11% in patients age 50 to 59, and 0% in patients age greater than or equal to 60. Contrary to other reports which have used different HiDAC regimens, we found no relationship between cytogenetics and EFS. Cytogenetics were defined as favorable risk: t(8;21), inv (16), and del (16); neutral risk: normal or t(15;17); and unfavorable risk: any abnormality not included in favorable risk or neutral risk. EFS was 29% +/- 17% inpatients with favorable cytogenetics, 37% +/- 14% in patients with neutralcytogenetics, and 31% +/- 12% in patients with unfavorable cytogenetics. These differences were not statistically significant. Because of the successful use of allogeneic transplantation at relapse in patients with matched related donors, five year actuarial survival (S) in this series was 40% +/- 6%. Five year actuarial survival was 57% +/- 9% for patients age : 44 and 25% +/- 8% for patients age greater than or equal to 45. This difference is statistically significant, p < .025. Clinicians should be cautious about making clinical decisions regarding consolidation therapy of ANLL on the basis of the presence or absence of cytogenetic abnormalities as the importanceof cytogenetics may depend on the specific therapy which is employed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/03/20 alle ore 10:53:03